Fennec Pharmaceuticals Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fennec Pharmaceuticals Inc. (Nasdaq: FENC) on November 19, 2025, covering events occurring between November 13, 2025, and November 17, 2025. The filing details the final settlement of a senior secured floating rate convertible note agreement originally entered into with Petrichor Opportunities Fund I LP in August 2022.
Key Financial Metrics and Transaction Details
The Company fully repurchased and redeemed the remaining outstanding notes from Petrichor on November 17, 2025. The transaction eliminated all payment obligations under the original $30 million note facility.
| Component | Amount (USD) |
|---|---|
| Outstanding Principal (incl. accrued PIK interest) | $19,476,655.48 |
| Accrued and Unpaid Interest | $305,134.27 |
| Redemption Fee (10% of principal) | $1,947,665.55 |
| Total Redemption Price | $21,729,455.30 |
The filing text does not provide specific data on current revenue, operating profit, cash flow, or remaining liquidity balances outside of this transaction.
Material Changes
- Debt Elimination: The Company satisfied all obligations related to the Petrichor Notes, reducing its debt load by approximately $19.5 million in principal and removing associated interest obligations.
- Cash Outflow: The Company incurred a cash outflow of approximately $21.7 million to settle the debt.
- Historical Context: This transaction follows a partial redemption of $13 million in notes completed on December 18, 2024.
Outlook, Risks, and Management Commentary
Management confirmed that all payment obligations under the Notes have been satisfied in full. The filing references a press release issued on November 19, 2025, regarding this event. No specific forward-looking guidance, risk factors, or contingencies beyond the completion of this debt settlement are detailed in this specific 8-K filing.
Key Facts for Investor Verification
- Verify the Company's remaining cash and cash equivalents post-redemption to assess liquidity runway.
- Confirm the impact of the $21.7 million cash outflow on the Company's balance sheet in the next quarterly filing (10-Q).
- Review the attached Waiver and Redemption Agreement (Exhibit 10.1) for any remaining covenants or conditions.
- Check for any new financing arrangements announced concurrently to replace the retired debt capacity.